Advertisement

Fundamentals of Cancer Treatment

Effects of Chemotherapy on Neoplastic Cells
  • Sujith Kalmadi
  • Derek Raghavan
Part of the Current Clinical Oncology book series (CCO)

Abstract

Cytotoxic chemotherapy evolved from the concepts of Lissauer and Ehrlich over the last century. The initial chemotherapy protocols they devised were characterized by a lack of specificity, and walking a fine line balancing the toxicities experienced by the host and the tumor. This has been subsequently improved owing to a better understanding of tumor biology and the biochemical basis of action of the chemotherapy regimens. Radiation therapy started after the discovery of X-rays by Roentgen in 1895. Refinement of these modalities has resulted in therapeutic options for patients with several types of malignancies. Innovative modern techniques in the 1990s have provided insight into the intracellular pathways that result in sensitivity and resistance of the neoplastic cells to drug treatment.

Keywords

Vascular Endothelial Growth Factor Chronic Lymphocytic Leukemia Polycythemia Vera Antineoplastic Agent Vinca Alkaloid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Tannock IF. Cell kinetics and chemotherapy. A critical review. Cancer Treat Rep 1978; 62:1117–1133.PubMedGoogle Scholar
  2. 2.
    Young RC, De Vita VT. Cell cycle characteristics of human solid tumors in vivo. Cell Tissue Kinet 1970; 3:285–290.PubMedGoogle Scholar
  3. 3.
    Alberts DS. A unifying vision of cancer therapy for the 21st century. J Clin Oncol 1999; 17:13–21.PubMedGoogle Scholar
  4. 4.
    Yankee RA, De Vita VT, Perry S. The cell cycle of leukemia L 1210 cells in vivo. Cancer Res 1968; 27:2381–2385.Google Scholar
  5. 5.
    Skipper HE, Schabel FM, Wilcox WS. Experimental evaluation of potential anticancer agents XII: on the criteria and kinetics associated with “curability of leukemia”. Cancer Chemother Rep 1964; 35:1–111PubMedGoogle Scholar
  6. 6.
    Schnipper L. Clinical implications of tumor-cell heterogeneity. N Engl J Med 1986; 314:1423–1431.PubMedGoogle Scholar
  7. 7.
    Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57–70.PubMedCrossRefGoogle Scholar
  8. 8.
    Tubiana M. Tumor cell proliferation kinetics and tumor growth rate. Acta Oncol 1989; 28:113–121.PubMedCrossRefGoogle Scholar
  9. 9.
    Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58:1408–1416.PubMedGoogle Scholar
  10. 10.
    Nowell PC. The clonal evolution of tumor progression. Science 1976; 194:23–28.PubMedCrossRefGoogle Scholar
  11. 11.
    Nowell P: Mechanisms of tumor progression. Cancer Res 1986; 46:2203–2207.PubMedGoogle Scholar
  12. 12.
    Steel GG. The growth kinetics of tumors in relation to their therapeutic response. Laryngoscope 1975; 85:359–370.PubMedCrossRefGoogle Scholar
  13. 13.
    Coldman AJ, Goldie JH. Impact of dose-intense chemotherapy on the development of permanent drug resistance. Semin Oncol 1987; 14:29–33.PubMedGoogle Scholar
  14. 14.
    Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986; 70:163–169.PubMedGoogle Scholar
  15. 15.
    Norton LA. A gompertzian model of human breast cancer growth. Cancer Res 1988; 48:7067–7071.PubMedGoogle Scholar
  16. 16.
    Steel GG, Adams GE, Peckham MJ, eds. The Biologic Basis of Radiotherapy. The Netherlands: Elsevier; 1983:239–248.Google Scholar
  17. 17.
    Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996; 14:2590–2611.PubMedGoogle Scholar
  18. 18.
    Canal P, Chatelut E, Guichard S. Practical treatment guide for dose individualization in cancer chemotherapy. Drugs 1998; 56:1019–1038.PubMedCrossRefGoogle Scholar
  19. 19.
    Iyer L, Ratain MJ. Pharmacogenetics and cancer chemotherapy. Eur J Cancer 1998; 34:1493–1499.PubMedCrossRefGoogle Scholar
  20. 20.
    Ratain MJ, Schilsky RL, Conley BA, Egorin MJ. Pharmacodynamics in cancer therapy. J Clin Oncol 1990; 8:1739–1753.PubMedGoogle Scholar
  21. 21.
    Wagner JG. Kinetics of Pharmacologic Response. I. Proposed relationships between response and drug concentration in the intact animal and man. J Theor Biol 1968; 20:173–201.PubMedCrossRefGoogle Scholar
  22. 22.
    Endicott JA, Ling V. The biochemistry of P-glycoprotein mediated multidrug resistance. Annu Rev Biochem 1989; 58:137–171.PubMedCrossRefGoogle Scholar
  23. 23.
    Goldstein LJ, Galski H, Fojo A, et al. Expression of multidrug resistance gene in human tumors. J Natl Cancer Inst 1989; 81:116–124.PubMedCrossRefGoogle Scholar
  24. 24.
    Hickman JA. Apoptosis and chemotherapy resistance. Eur J Cancer 1996; 32A:921–926.PubMedCrossRefGoogle Scholar
  25. 25.
    Schmitt CA, Lowe SW. Apoptosis and therapy. J Pathol 1999; 187:127–137.PubMedCrossRefGoogle Scholar
  26. 26.
    Moolgavkar SH, Knudsen AG. Mutation and cancer: a model for human carcinogenesis. J Natl Cancer Inst 1981; 66:1037–1052.PubMedGoogle Scholar
  27. 27.
    Fearon EC. Human cancer syndromes: clues to the origin and nature of cancer. Science 1997; 278:1043–1058.PubMedCrossRefGoogle Scholar
  28. 28.
    Sikic BL. Modulation of multidrug resistance: at the threshold. J Clin Oncol 1993; 11:1629–1635.PubMedGoogle Scholar
  29. 29.
    DeVita VT, Schein PS. The use of drugs in combination for the treatment of cancer: rationale and results. N Engl J Med 1973; 228:998–1006.Google Scholar
  30. 30.
    Skipper HE. Critical variables in the design of combination chemotherapy regimens to be used alone or in adjuvant settings. Colloque INSERM 1986; 137:11.Google Scholar
  31. 31.
    Hyrniuk WM. Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 1987:14:65–74.Google Scholar
  32. 32.
    Day RS. Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy. Cancer Res 1986; 46:3876–3885.PubMedGoogle Scholar
  33. 33.
    Therasse P, Arbuck S, Eisenhauer E, et al. New guidelines to evaluate the response to treatment of solid tumors. J Natl Cancer Inst 2000; 92:205–216.PubMedCrossRefGoogle Scholar
  34. 34.
    Frei E III. Curative cancer chemotherapy. Cancer Res 1985; 45:6523–6537.PubMedGoogle Scholar
  35. 35.
    Krakoff IH. Systemic treatment of cancer. CA Cancer J Clin 1996; 46:137–141.CrossRefGoogle Scholar
  36. 36.
    Rideout DC, Chou TC. Synergism, potentiation and antagonism in chemotherapy. An overview. In: Chou TC, Rideout DC, eds. Synergism and Antagonism in Chemotherapy. San Diego, CA: Academic Press; 1991:3.Google Scholar
  37. 37.
    Henderson IC, Gelman RS, Harris JR, Canellos GP. Duration of therapy in adjuvant chemotherapy trials. NCI Monogr 1986; 1:95–98.PubMedGoogle Scholar
  38. 38.
    Hellman S. Stopping metastases at their source. N Engl J Med 1997; 337:996–997.PubMedCrossRefGoogle Scholar
  39. 39.
    Collins M. Pharmacokinetic rationale for regional drug delivery. J Clin Oncol. 1984; 2:498–504.PubMedGoogle Scholar
  40. 40.
    Perry MC, ed. The Chemotherapy Sourcebook. 3rd ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2001.Google Scholar

Copyright information

© Humana Press, Inc., Totowa, NJ 2006

Authors and Affiliations

  • Sujith Kalmadi
    • 1
  • Derek Raghavan
    • 1
  1. 1.Department of Hematology and Medical Oncology, Taussig Cancer CenterThe Cleveland Clinic FoundationCleveland

Personalised recommendations